

S 3991

American Made Pharmaceuticals Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 5, 2022

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Apr 5, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/3991>

Sponsor

Name: Sen. Smith, Tina [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cotton, Tom [R-AR]	R · AR		Apr 5, 2022

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Apr 5, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 7400	Identical bill	Apr 6, 2022: Referred to the Subcommittee on Health.

Summary (as of Apr 5, 2022)

American Made Pharmaceuticals Act of 2022

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain.

Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Actions Timeline

- **Apr 5, 2022:** Introduced in Senate
- **Apr 5, 2022:** Read twice and referred to the Committee on Finance.